OPTIMIZATION OF ALEMTUZUMAB DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR REDUCED INTENSITY TRANSPLANTATION FROM UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES

被引：2
|
作者：
Gupta, V [1 ]
Xu, W. [1 ]
Sutherland, R. [2 ]
Kamel-Reid, S. [2 ]
Kuruvilla, J. [1 ]
Loach, D. [1 ]
Lipton, J. H. [1 ]
Messner, H. A. [1 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2009年 / 15卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2008.12.383
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
348
引用
收藏
页码：124 / 125
页数：2
相关论文
共 50 条
  • [31] Reduced-intensity unrelated cord blood transplantation for patients with hematologic malignancies
    Miyakoshi, Shigesaburo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (11) : 1218 - 1218
  • [32] A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.
    Charlton, Andrew
    Spence, Laura
    Bigley, Venetia
    Groves, Natasha
    Hale, Geoff
    Pagan, Sarah
    Turner, Brie E.
    Jones, Gail
    Jackson, Graham H.
    Dickinson, Anne M.
    Collin, Matthew
    BLOOD, 2009, 114 (22) : 1293 - 1293
  • [33] USE OF MYCOPHENOLATE MOFETIL FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM UNRELATED DONORS
    Abagnale, Davide Pio
    Cacace, Andrea
    Gaeta, Giuseppe
    Giannattasio, Maria Luisa
    Piccolo, Linda
    Grimaldi, Francesco
    Avilia, Simona
    Memoli, Mara
    Ammirati, Lucia
    Maglione, Valentina
    Severino, Alessandro
    Califano, Catello
    Pane, Fabrizio
    Battipaglia, Giorgia
    BONE MARROW TRANSPLANTATION, 2024, 59 : 346 - 347
  • [34] Graft-Versus-Host Disease Prophylaxis with Antithymocyte Globulin in Patients Receiving Stem Cell Transplantation from Unrelated Donors: An Observational Retrospective Single-Center Study
    Lo Schirico, Mariella
    Passera, Roberto
    Gill, Jessica
    Dellacasa, Chiara
    Dogliotti, Irene
    Giaccone, Luisa
    Zompi, Sofia
    Busca, Alessandro
    CANCERS, 2023, 15 (10)
  • [35] Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation
    Kean, Leslie S.
    Burns, Linda J.
    Kou, Tzuyung D.
    Kapikian, Roxanne
    Lozenski, Karissa
    Langston, Amelia
    Horan, John T.
    Watkins, Benjamin
    Qayed, Muna
    Bratrude, Brandi
    Betz, Kayla
    Tang, Xiao-Ying
    Zhang, Mei-Jie
    Connolly, Sean E.
    Polinsky, Martin
    Gavin, Brian
    Gomez-Caminero, Andres
    Pasquini, Marcelo C.
    BLOOD, 2024, 144 (17) : 1834 - 1845
  • [36] Lowering the dose of in vivo alemtuzumab (Campath-1H) in reduced intensity conditioning for allogeneic transplantation results in more graft-versus-host disease.
    Thomson, K
    Hart, D
    Cook, G
    Milligan, D
    Parker, A
    Marsh, J
    Chopra, R
    Littlewood, T
    Linch, D
    Goldstone, A
    Morris, E
    Hale, G
    Peggs, K
    Mackinnon, S
    BLOOD, 2003, 102 (11) : 712A - 713A
  • [37] PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING UNRELATED DONOR BONE-MARROW TRANSPLANTATION
    PHILLIPS, GL
    NEVILL, TJ
    SPINELLI, JJ
    NANTEL, SH
    KLINGEMANN, HG
    BARNETT, MJ
    SHEPHERD, JD
    CHAN, KW
    MEHARCHAND, JM
    SUTHERLAND, HJ
    REECE, DE
    MESSNER, HA
    BONE MARROW TRANSPLANTATION, 1995, 15 (02) : 213 - 219
  • [38] SIROLIMUS IN COMBINATION WITH CYCLOSPORINE OR TACROLIMUS PLUS METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION FROM UNRELATED DONORS
    Furlong, T.
    H.-P, Kiem
    Appelbaum, F. R.
    Carpenter, P. A.
    Deeg, J.
    Doney, K.
    Flowers, M. E. D.
    Mielcarek, M.
    Nash, R. A.
    Storh, R.
    Martin, P. J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 140 - 141
  • [39] CHRONIC GRAFT VERSUS HOST DISEASE AND PRETRANSPLANT DISEASE STATUS PREDICT OUTCOMES IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION
    Shah, M.
    Agha, M.
    Mapara, M.
    Lenhart, K.
    Raptis, A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 119 - 119
  • [40] Chronic graft versus host disease and pretransplant disease status predict outcomes in patients with hematologic malignancies undergoing reduced intensity allogeneic stem cell transplantation
    Shah, Megha A.
    Agha, Mounzer
    Mapara, Markus
    Lenhart, Kate
    Raptis, Anastasios
    BLOOD, 2007, 110 (11) : 353B - 354B
12345